ABCB11 and benign recurrent intrahepatic cholestasis: Nevertheless, we speculate that anti-miR-33 oligonucleotides might be useful to manage patients who develop BRIC as a consequence of partial loss of expression and/or function of ABCB11 or ATP8B1.